Show simple item record

dc.contributor.authorMaleki-Yazdi, M. Reza
dc.contributor.authorMolimard, Mathieu
dc.contributor.authorKeininger, Dorothy L
dc.contributor.authorGruenberger, Jean-Bernard
dc.contributor.authorCarrasco, Joao
dc.contributor.authorPitotti, Claudia
dc.contributor.authorSauvage, Elsa
dc.contributor.authorChehab, Sara
dc.contributor.authorPrice, David Brendan
dc.date.accessioned2017-08-11T23:01:25Z
dc.date.available2017-08-11T23:01:25Z
dc.date.issued2016-10
dc.identifier.citationMaleki-Yazdi , M R , Molimard , M , Keininger , D L , Gruenberger , J-B , Carrasco , J , Pitotti , C , Sauvage , E , Chehab , S & Price , D B 2016 , ' Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease : Analyses Conducted for Canada, France, Italy, and Portugal ' Applied Health Economics and Health Policy , vol 14 , no. 5 , pp. 579-594 . DOI: 10.1007/s40258-016-0256-zen
dc.identifier.issn1175-5652
dc.identifier.otherPURE: 70096639
dc.identifier.otherPURE UUID: be686c44-f5ce-400c-aecc-290d44092025
dc.identifier.otherScopus: 84981517775
dc.identifier.urihttp://hdl.handle.net/2164/9140
dc.descriptionAcknowledgments The authors would like to thank Purnima Pathak (Novartis) for providing writing assistance in the development of this manuscript. The authors would also like to thank Colin Burke and Ronan Mahon (Health Economic Modelers; Novartis) for their modeling support. Medical writing support was funded by Novartis Pharma AG (Basel, Switzerland).en
dc.format.extent16en
dc.language.isoeng
dc.relation.ispartofApplied Health Economics and Health Policyen
dc.rightsThe final publication is available at Springer via http://dx.doi.org/10.1007/s40258-016-0256-zen
dc.subjectR Medicineen
dc.subject.lccRen
dc.titleCost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease : Analyses Conducted for Canada, France, Italy, and Portugalen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen, Medicine, Medical Sciences & Nutrition, Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen, Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPostprinten
dc.identifier.doihttp://dx.doi.org/10.1007/s40258-016-0256-z
dc.date.embargoedUntil11-08-20


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record